Speaking at AAPS PharmSci 360, Dr Stephanie Johnson, a principal formulation scientist at Pfizer, details how platform formulations save time before commitment, shift risk downstream, and what AI tools need to earn trust.
Stephanie Johnson
Advertisement
Stephanie Johnson, PhD, is principal scientist, Formulation Development, at Pfizer.
Articles by Stephanie Johnson
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
3
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
4
The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis
5